Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.86 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.86 |
| ▸ | LMNA | P02545 | 3/20 | 0.86 |
| ▸ | MAPT | P10636 | 2/20 | 0.86 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.86 |
| ▸ | THPO | P40225 | 2/20 | 0.86 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.86 |
| ▸ | GMNN | O75496 | 1/20 | 0.86 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.86 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.86 |
| ▸ | TSHR | P16473 | 1/20 | 0.86 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.86 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.86 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.86 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.63 |
| ▸ | EGFR | P00533 | 2/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorambucil SCHEMBL28344179 | 0.94 | SMN1; SMN2 (0.86) | SMN1; SMN2ALDH1A1HIF1ALMNAMAPT | |
| Chlorambucil SCHEMBL17803700 | 0.93 | SMN1; SMN2 (0.89) | SMN1; SMN2ALDH1A1HIF1ALMNAMAPT | |
| Chlorambucil SCHEMBL28272037 | 0.93 | SMN1; SMN2 (0.94) | SMN1; SMN2ALDH1A1HIF1ALMNAMAPT | |
| Chlorambucil SCHEMBL4308 | 0.93 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1HIF1ALMNAMAPT | |
| Chlorambucil SCHEMBL5318105 | 0.93 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1HIF1ALMNAMAPT | |
| Chlorambucil SCHEMBL28694332 | 0.92 | ALDH1A1 (0.82) | SMN1; SMN2ALDH1A1HIF1ALMNAMAPT | |
| Chlorambucil SCHEMBL28942852 | 0.92 | SMN1; SMN2 (0.91) | SMN1; SMN2ALDH1A1HIF1ALMNAMAPT | |
| Chlorambucil SCHEMBL28743193 | 0.92 | SMN1; SMN2 (0.91) | SMN1; SMN2ALDH1A1HIF1ALMNAMAPT | |
| Chlorambucil SCHEMBL23753952 | 0.91 | SMN1; SMN2 (0.97) | SMN1; SMN2ALDH1A1HIF1ALMNAMAPT | |
| Chlorambucil SCHEMBL5846926 | 0.91 | SMN1; SMN2 (0.97) | SMN1; SMN2ALDH1A1HIF1ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160106837-A1 | COMBINATION OF CD37 ANTIBODIES WITH CHLORAMBUCIL | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-21 | — | — | US | disclosed |
| US-8216571-B2 | Fully human anti-VEGF antibodies and methods of using | SCHERING CORPORATION (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | XOMA TECHNOLOGY LTD. | 2011-04-28 | — | — | US | disclosed |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | MERCK SHARP & DOHME CORP. | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | VEGFA, KDR, FLT4 | SMN1; SMN2 4415/4885ALDH1A1 3461/4885HIF1A 114/4885 |
| US-20160106837-A1 | COMBINATION OF CD37 ANTIBODIES WITH CHLORAMBUCIL | CD22, SIGLEC7, CD2 | SMN1; SMN2 4564/4885ALDH1A1 941/4885HIF1A 1051/4885 |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | IGF1R, IGFBP1, IGFBP2 | SMN1; SMN2 2063/4885ALDH1A1 2432/4885HIF1A 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.